Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 05/18/2026

ABP vs. APVO, FLGC, BGMS, CUPR, and ENTO

Should you buy Abpro stock or one of its competitors? MarketBeat compares Abpro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abpro include Aptevo Therapeutics (APVO), Flora Growth (FLGC), Cyclacel Pharmaceuticals (BGMS), Cuprina Holdings (Cayman) (CUPR), and Entero Therapeutics (ENTO). These companies are all part of the "pharmaceutical products" industry.

How does Abpro compare to Aptevo Therapeutics?

Abpro (NASDAQ:ABP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Abpro is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A

In the previous week, Aptevo Therapeutics had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 0 mentions for Abpro. Aptevo Therapeutics' average media sentiment score of 0.33 beat Abpro's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Aptevo Therapeutics	Neutral

23.3% of Abpro shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abpro's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Aptevo Therapeutics beats Abpro on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to Flora Growth?

Abpro (NASDAQ:ABP) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Abpro has higher earnings, but lower revenue than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Flora Growth	$57.61M	0.08	-$15.91M	-$32.49	N/A

In the previous week, Abpro's average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Flora Growth	Neutral

23.3% of Abpro shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abpro has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Abpro's return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Flora Growth	-32.03%	-64.02%	-34.46%

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 617.70%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Abpro and Flora Growth tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Abpro (NASDAQ:ABP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Abpro's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-53.19%	-45.03%
Abpro	N/A	N/A	-344.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for Abpro. Cyclacel Pharmaceuticals' average media sentiment score of 0.99 beat Abpro's score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Abpro	Neutral

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 13.7% of Abpro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has higher revenue and earnings than Abpro. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.15	-$3M	-$4.54	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Summary

Cyclacel Pharmaceuticals beats Abpro on 7 of the 11 factors compared between the two stocks.

How does Abpro compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Abpro (NASDAQ:ABP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Abpro	N/A	N/A	-344.76%

23.3% of Abpro shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cuprina Holdings (Cayman)'s average media sentiment score of 1.89 beat Abpro's score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Very Positive
Abpro	Neutral

Cuprina Holdings (Cayman) has higher revenue and earnings than Abpro.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$40K	135.98	-$3.63M	N/A	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Summary

Cuprina Holdings (Cayman) beats Abpro on 4 of the 7 factors compared between the two stocks.

How does Abpro compare to Entero Therapeutics?

Abpro (NASDAQ:ABP) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Entero Therapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Abpro's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Entero Therapeutics had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Abpro. Entero Therapeutics' average media sentiment score of 0.75 beat Abpro's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Entero Therapeutics	Positive

23.3% of Abpro shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Abpro beats Entero Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.27B	$6.28B	$12.06B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-0.12	18.59	20.65	25.03
Price / Sales	N/A	280.35	547.58	77.55
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	-0.06	6.58	9.72	6.58
Net Income	-$7.23M	$24.35M	$3.56B	$335.49M
7 Day Performance	N/A	-3.03%	-1.79%	-1.87%
1 Month Performance	N/A	-4.08%	-2.66%	-1.90%
1 Year Performance	-93.60%	52.51%	29.59%	26.67%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
APVO Aptevo Therapeutics	1.3457 of 5 stars	$4.76 -1.4%	N/A	-96.0%	$5.62M	N/A	N/A	50	Earnings Report
FLGC Flora Growth	1.6315 of 5 stars	$5.35 +15.1%	$30.00 +460.7%	-84.1%	$5.60M	$57.61M	N/A	280	Gap Up
BGMS Cyclacel Pharmaceuticals	1.4399 of 5 stars	$1.00 +6.4%	N/A	N/A	$5.52M	$750K	N/A	14	Positive News Earnings Report Short Interest Decrease Gap Down
CUPR Cuprina Holdings (Cayman)	1.2188 of 5 stars	$0.26 +5.6%	N/A	N/A	$5.50M	$40K	N/A	14	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. APVO, FLGC, BGMS, CUPR, and ENTO

How does Abpro compare to Aptevo Therapeutics?

Summary

How does Abpro compare to Flora Growth?

Summary

How does Abpro compare to Cyclacel Pharmaceuticals?

Summary

How does Abpro compare to Cuprina Holdings (Cayman)?

Summary

How does Abpro compare to Entero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. APVO, FLGC, BGMS, CUPR, and ENTO

How does Abpro compare to Aptevo Therapeutics?

Which has stronger valuation & earnings, ABP or APVO?

Does the media prefer ABP or APVO?

Do insiders and institutionals have more ownership in ABP or APVO?

Is ABP or APVO more profitable?

Do analysts recommend ABP or APVO?

Summary

How does Abpro compare to Flora Growth?

Which has higher valuation & earnings, ABP or FLGC?

Does the media favor ABP or FLGC?

Do insiders & institutionals believe in ABP or FLGC?

Is ABP or FLGC more profitable?

Do analysts recommend ABP or FLGC?

Summary

How does Abpro compare to Cyclacel Pharmaceuticals?

Is BGMS or ABP more profitable?

Do analysts prefer BGMS or ABP?

Does the media favor BGMS or ABP?

Do institutionals & insiders believe in BGMS or ABP?

Which has higher earnings & valuation, BGMS or ABP?

Summary

How does Abpro compare to Cuprina Holdings (Cayman)?

Do analysts rate CUPR or ABP?

Is CUPR or ABP more profitable?

Do institutionals and insiders hold more shares of CUPR or ABP?

Does the media refer more to CUPR or ABP?

Which has preferable valuation & earnings, CUPR or ABP?

Summary

How does Abpro compare to Entero Therapeutics?

Which has higher valuation & earnings, ABP or ENTO?

Is ABP or ENTO more profitable?

Do analysts recommend ABP or ENTO?

Does the media prefer ABP or ENTO?

Do institutionals & insiders have more ownership in ABP or ENTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools